A study of COTI-219.
Phase of Trial: Phase I
Latest Information Update: 15 Nov 2017
At a glance
- Drugs COTI 219 (Primary)
- Indications Cancer; Colorectal cancer; Small cell lung cancer
- Focus Adverse reactions
- 15 Nov 2017 According to a Critical Outcome Technologies media release, the company plans to file an IND in early 2018.
- 16 Jan 2017 Indications are assumed from RDI profile.
- 16 Jan 2017 New trial record